Final policy recommendations
based on the report are
available
here.
Press Release
Biotech needs the right
policies to stay on track in
new EU Member States
Brussels,
25 September 2009
EuropaBio, the European
Association for
Bioindustries, and Venture
Valuation, with the
collaboration of national
stakeholders,
yesterday published a ground-breaking report
“Biotech in the new EU
Member States: an emerging
sector”, evaluating the
biotech industry across the
12 newest EU Member State,
as well as Turkey and
Croatia.
The report identifies 260
biotechnology companies
across 14 countries; and
addresses the opportunities
and challenges particular to
each national situation.
Four countries in
particular, Hungary, Poland,
the Czech Republic, and
Estonia, report the highest
numbers of biotechnology
companies and were the most
developed biotechnology
sectors among the 14
countries
analysed. One of the main challenges for the sector
highlighted
in the report is how to turn
innovation into products
when there is little
guidance and support.
“Despite the political will
to develop R&D as a national
priority and government
interest in biotechnology,
concrete policies are not
always put into practice.”
said Patrik Frei, CEO
of Venture Valuation and
co-author of the report. He
continued, “Setting up a
coherent and consistent
framework with support
dedicated to the
biotechnology and healthcare
sectors is the key to
long-term success for the
industry.”
“Capacity building
on intellectual property
rights and patenting, as
well as effective technology
transfer offices are needed
to stimulate
commercialisation,
“ said Willy De Greef,
Secretary General of
EuropaBio and co-author of
the report. “While
achievements of the sector
are not yet visible in terms
of products on the market,
it is important to
acknowledge that a solid
foundation is emerging in
these countries to bring
about future successful
developments of the
biotechnology sector.”
In addition to the report,
recommendations to the EU
and national governments
were formulated during
workshops in Budapest,
Prague and Vilnius, to
improve the policy
environment for
biotechnology companies.
-ENDS-
14 AllBio
Project: Policy
Recommendations
Camille Burel,
14AllBio project coordinator
at EuropaBio, presents
policy recommendations to
foster biotech development
in the 12 new Member States
as well as Turkey and
Croatia. The 14AllBio
project provided an analysis
of the development of the
biotech sector in the
region, thereby filling the
information gap compared to
previous studies. For more
details see the PowerPoint presentation.
Get the Facts: Biotech SMEs
: Time to Act Hear first-hand the struggle
that the CEO of a biotech SME has navigating access to
finance in the EU. Thomas Saylor, chair of EuropaBio's SME
Platform, introduces concrete actions that need to take
place for biotech SMEs to survive the financial crisis and
thrive in Europe.
14AllBio Project - Results
Kasia Galecka from Venture
Valuation presents the main
findings of the 14AllBio project
on the state of biotech
development in the 12 new Member
States as well as Turkey and
Croatia. The 14AllBio project
provided an analysis of the
development of the biotech
sector in the region, thereby
filling the information gap
compared to previous studies.
For more details, see the
PowerPoint presentation
